A lifestyle intervention program for successfully addressing major cardiometabolic risks in persons with SCI: a three-subject case series.
A lifestyle intervention program for successfully addressing major cardiometabolic risks in persons with SCI: a three-subject case series.
复制标题
DOI：
10.1038/scsandc.2017.7
复制
发表时间：
2017-01-01
影响因子：
1.2
通讯作者：
Nash, Mark S
中科院分区：
文献类型：
--
作者：
Bigford, Gregory E;Mendez, Armando J;Nash, Mark S
简介：本研究是一个前瞻性的病例系列分析的影响，一个全面的生活方式干预计划在三个慢性截瘫患者具有重大风险的cardiometabolic syndrome（CMS）.CASE介绍：个人经历了激烈的6个月的计划，电路阻力锻炼，营养使用地中海饮食和行为支持，随后由6个月的扩展（维护）阶段，涉及最小的支持。主要目标是体重减少7%。其他结果分析胰岛素抵抗使用HOMA-IR模型，空腹甘油三酯和高密度脂蛋白胆固醇的血浆水平。所有参与者都达到了体重减少7%的目标，并在MP后保持了体重减少。在2/3例受试者中观察到HOMA-IR和高密度脂蛋白胆固醇改善。所有参与者提高他们的风险血浆triglycerids.Discussion：我们的结论是，在一个三人的情况下，一系列的人与慢性截瘫，一种生活方式的干预方案，涉及电路阻力训练，热量限制Mediterranean式的饮食和行为支持，结果在临床上显着的损失，体重和有效地降低组件风险CMS和糖尿病。这些结果在6个月的MP（涉及最低限度的监督）后大部分得以维持。
INTRODUCTION: This study is a prospective case series analyzing the effects of a comprehensive lifestyle intervention program in three patients with chronic paraplegia having major risks for the cardiometabolic syndrome (CMS).CASE PRESENTATION: Individuals underwent an intense 6-month program of circuit resistance exercise, nutrition using a Mediterranean diet and behavioral support, followed by a 6-month extension (maintenance) phase involving minimal support. The primary goal was a 7% reduction of body mass. Other outcomes analyzed insulin resistance using the HOMA-IR model, and plasma levels of fasting triglycerides and high-density lipoprotein cholesterol. All participants achieved the goal for 7% reduction of body mass and maintained the loss after the MP. Improvements were observed in 2/3 subjects for HOMA-IR and high-density lipoprotein cholesterol. All participants improved their risk for plasma triglycerides.DISCUSSION: We conclude, in a three-person case series of persons with chronic paraplegia, a lifestyle intervention program involving circuit resistance training, a calorie-restrictive Mediterranean-style diet and behavioral support, results in clinically significant loss of body mass and effectively reduced component risks for CMS and diabetes. These results were for the most part maintained after a 6-month MP involving minimal supervision.